SCHEMBL24933683

SCHEMBL24933683

NC(=O)c1cc(-c2ccc(OCc3cccs3)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.41
HPGD P15428 2/20 0.39
F9 P00740 1/20 0.38
F10 P00742 1/20 0.38
HSD17B1 P14061 4/20 0.37
HSD17B2 P37059 4/20 0.37
MAPT P10636 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
MAOB P27338 3/20 0.36
FFAR1 O14842 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
MAPK8 P45983 1/20 0.35
S1PR4 O95977 2/20 0.35
S1PR1 P21453 2/20 0.35
S1PR3 Q99500 2/20 0.35
S1PR5 Q9H228 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933507 0.85 PARP15 (0.53) HSD17B1HSD17B2CDK5CDK5R1
SCHEMBL24933690 0.85 BTK (0.44) HSD17B1HSD17B2FFAR1CDK5CDK5R1
SCHEMBL24933349 0.85 GSTP1 (0.50) HSD17B1HSD17B2MAOBFFAR1
SCHEMBL24933671 0.84 MAOB (0.56) MAOBFFAR1PPARGPPARA
SCHEMBL24933222 0.84 PRKAB2 (0.44) HSD17B1HSD17B2MAOBCDK5CDK5R1
SCHEMBL24932953 0.83 PARP15 (0.43) HPGDHSD17B1HSD17B2MAOBFFAR1
SCHEMBL24933256 0.83 PDK2 (0.43) PDK2HSD17B1HSD17B2FFAR1
SCHEMBL24933646 0.83 MAOB (0.44) HSD17B1HSD17B2MAOBFFAR1CDK5
SCHEMBL24933002 0.83 HSD17B1 (0.38) HSD17B1HSD17B2CDK5CDK5R1
SCHEMBL30240782 0.81 MAOB (0.52) MAPTMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed